enVVeno Medical Corporation (NVNO) 株式分析

企業概要

enVVeno Medical Corporation is a clinical-stage medical device company dedicated to developing bioprosthetic tissue-based solutions designed to improve the standard of care in the treatment of venous disease. This enterprise operates within the healthcare sector, specifically focusing on the medical devices industry, which typically involves high regulatory hurdles and significant research and development expenditures before products reach commercialization. The company's total market capitalization stands at $6.77M, while its reported annual revenue is N/A, and the organization employs a workforce of 33 individuals. These valuation and operational metrics indicate that enVVeno is a small-cap entity with minimal current revenue generation relative to its market cap, suggesting the company is likely in an early stage of development where equity value is driven primarily by potential future product success rather than existing cash flows or sales volume.

財務健全性

The company's financial performance is characterized by a Net Income (TTM) of $-19,472,000 and an EBITDA of $-20,763,000, while the Revenue (TTM) is N/A. The substantial gap between revenue and net income, compounded by the lack of reported revenue figures, reveals a cost structure dominated by operating expenses and R&D investments that are not yet offset by commercial sales. The Free Cash Flow stands at $-9,209,875, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or additional financing events. When analyzing profitability metrics, the Gross Margin is 0.0%, the Operating Margin is 0.0%, and the Profit Margin is 0.0%, reflecting that the company has not yet achieved profitable commercial operations to generate positive margins on its sales or expenses. On the balance sheet, the company holds $28.21M in Cash against $700,000 in Debt, resulting in a Debt to Equity ratio of 2.58, which suggests a highly leveraged position relative to equity despite the absolute debt amount being low, a common dynamic in early-stage biotech firms where equity dilution can occur. The Current Ratio is 13.58, indicating an extremely strong short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer for operational continuity despite cash burn. Regarding return metrics, the Return on Equity is -56.2% and the Return on Assets is -35.1%, revealing that management is currently generating negative returns on both shareholder equity and total assets due to the absence of net income.

バリュエーション評価

The valuation metrics present a complex picture given the company's financial stage, with a Trailing P/E (TTM) listed as N/A and a Forward P/E of -8.68. The discrepancy between a non-existent trailing P/E and a negative forward P/E implies that the market is valuing the company based on future expectations rather than historical earnings, as negative forward earnings typically result from projected losses or losses that are not yet reflected in trailing multiples. The Price to Book ratio is 0.25, which indicates that the market is currently pricing the company at a significant discount to its book value, suggesting investors are not paying a premium for the underlying assets of the firm. Since Revenue (TTM) is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at 1.00, these alternative metrics suggest the valuation is heavily weighted toward enterprise value relative to earnings power, rather than revenue or book value multiples. The stock has exhibited significant volatility, trading between a 52-Week High of $196.70 and a 52-Week Low of $8.67, placing the current price context within a range that reflects extreme investor sentiment swings. The Beta value is 1.09, which means the stock's price volatility is slightly higher than the broader market average, indicating that price movements in NVNO tend to amplify market shifts by approximately 9%.

Growth & Income

The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which precludes a direct comparison of whether earnings are growing faster or slower than revenue at this specific moment in the company's lifecycle. Because the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, it does not distribute dividends to shareholders, a strategy typical for clinical-stage companies that must reinvest all available earnings and cash reserves into growth initiatives such as product development and clinical trials. This reinvestment approach is necessary to transition the company from a clinical-stage entity to a revenue-generating business before any dividend payments can become sustainable or relevant. Consequently, the overall growth and income profile of enVVeno Medical Corporation is defined by a focus on capital appreciation potential and product development milestones rather than current income generation or dividend payouts.